Scarica l'app Stockscreener
2.59
1.89%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
X4 Pharmaceuticals Secures New $150 Million Term Loan - The Globe and Mail
XFOR: X4 Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
X4 Pharmaceuticals (XFOR) pairs a new loan with an approximately $78.7M debt payoff. - Stock Titan
No voting power is reported by Abigail P. Johnson in X4 Pharmaceuticals (XFOR)'s ownership amendment. - Stock Titan
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo Finance
Form 144 X4 Pharmaceuticals For: 1 October By Investing.com - Investing.com Nigeria
Form 144 X4 Pharmaceuticals For: 1 October By Investing.com - Investing.com UK
Medicenna Therapeutics Corp. (MDNAF) Stock Price, News, Quote & History - ca.finance.yahoo.com
Tax withholding requires a proposed 11,767-share sale by an X4 Pharmaceuticals (XFOR) officer. - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround - Yahoo Finance
Over 5.5M shares in X4 Pharmaceuticals (XFOR) now held by one investor group - Stock Titan
Assembly Biosciences (Nasdaq:ASMB)Stock Analysis - Simply Wall Street
X4 Pharmaceuticals, Inc. (XFOR) Latest Stock News & Headlines - Yahoo Finance
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook By Investing.com - Investing.com India
XFOR: Phase III enrollment for mavorixafor nears completion, with data and launch expected by early 2029 - TradingView
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
X4 Pharmaceuticals (NASDAQ: XFOR) Secures FDA Approval for Reduced Sample Size in 4WARD Trial, Data Expected in Early 2028 - Kalkine Media
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - markets.businessinsider.com
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - The Manila Times
Wells Fargo’s healthcare conference will include an X4 Pharmaceuticals talk Sept. 10 - Stock Titan
X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia - TipRanks
X4 posts updated corporate presentation; full 4WARD enrollment expected Q4 2026, topline data H1 2028 - TradingView
X4 Pharmaceuticals (XFOR) outlines path to possible 2029 FDA approval - Stock Titan
X4 Pharmaceuticals: FDA OKs Reduced Sample Size for 4WARD Phase 3, Enrollment to Finish by Year-End 2026 - TradingView
FDA backs smaller late-stage test of X4 (NASDAQ: XFOR) neutropenia drug, with pivotal data not due until 2028 - Stock Titan
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - Yahoo Finance
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportContinuation Pattern Picks - careplusvn.com
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportETF NAV Deviation - dars.gov.et
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportRTH Profile - dars.gov.et
X4 Pharmaceuticals (NasdaqCM:XFOR) Stock Forecast & Analyst Predictions - Simply Wall Street
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportMFI Overbought - www.dars.gov.et
X4 Pharmaceuticals Stock Price Forecast. Should You Buy XFOR? - StockInvest.us
ETFs Investing in X4 Pharmaceuticals, Inc. Stocks - tradingview.com
X4 Pharmaceuticals Inc. (XFOR) Peer Comparison – Compare with Others - Value Research
Camp4 CFO Kelly Gold buys $39,600 in company stock - investing.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New hires get 50,000 stock options from X4 Pharmaceuticals - Stock Titan
X4 Pharmaceuticals Inc. (XFOR) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):